Dyskinesia - Pipeline Review, H2 2016

Date: September 14, 2016
Pages: 170
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: DA5E756AD75EN
Leaflet:

Download PDF Leaflet

Dyskinesia - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Dyskinesia - Pipeline Review, H2 2016’, provides an overview of the Dyskinesia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Dyskinesia
  • The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects
  • The report assesses Dyskinesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Dyskinesia
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Dyskinesia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Dyskinesia Overview
Therapeutics Development
Pipeline Products for Dyskinesia - Overview
Pipeline Products for Dyskinesia - Comparative Analysis
Dyskinesia - Therapeutics under Development by Companies
Dyskinesia - Therapeutics under Investigation by Universities/Institutes
Dyskinesia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Dyskinesia - Products under Development by Companies
Dyskinesia - Products under Investigation by Universities/Institutes
Dyskinesia - Companies Involved in Therapeutics Development
Adamas Pharmaceuticals, Inc.
Addex Therapeutics Ltd
Advicenne
Astraea Therapeutics, LLC
Bionomics Limited
Catalyst Biosciences, Inc.
Catalyst Pharmaceuticals, Inc.
Clevexel Pharma SAS
Contera Pharma ApS
EpiVax, Inc.
Heptares Therapeutics Limited
Hua Medicine (Shanghai) Ltd.
Integrative Research Laboratories Sweden AB
Ipsen S.A.
Merz Pharma GmbH & Co. KgaA
MitoDys Therapeutics Limited
Neurim Pharmaceuticals Ltd
Neurocrine Biosciences, Inc.
Neurolixis Inc.
Osmotica Pharmaceutical Corp.
Otsuka Holdings Co., Ltd.
Phenomenome Discoveries, Inc.
Revance Therapeutics, Inc.
Sage Therapeutics, Inc.
SciFluor Life Sciences, LLC
SOM Innovation Biotech SL
Synchroneuron Inc.
Teva Pharmaceutical Industries Ltd.
Dyskinesia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dextromethorphan + quinidine sulfate) - Drug Profile
A2M-13677 - Drug Profile
abobotulinumtoxin A - Drug Profile
acamprosate calcium SR - Drug Profile
amantadine hydrochloride ER - Drug Profile
amantadine hydrochloride ER - Drug Profile
AT-127 - Drug Profile
AT-326 - Drug Profile
AT-403 - Drug Profile
befiradol - Drug Profile
CPP-115 - Drug Profile
CVXL-0107 - Drug Profile
deutetrabenazine ER - Drug Profile
dipraglurant ER - Drug Profile
dipraglurant IR - Drug Profile
Drug for Dyskinesia - Drug Profile
HTL-14242 - Drug Profile
incobotulinumtoxin A - Drug Profile
IRL-790 - Drug Profile
JM-010 - Drug Profile
MLR-1019 - Drug Profile
NBI-640756 - Drug Profile
Neu-120 - Drug Profile
Neu-240 - Drug Profile
onabotulinumtoxinA - Drug Profile
PEUN-3 - Drug Profile
PPI-1011 - Drug Profile
remeglurant - Drug Profile
RT-002 - Drug Profile
SAGE-217 - Drug Profile
sepranolone - Drug Profile
SK-609 - Drug Profile
Small Molecule for Dyskinesia - Drug Profile
Small Molecule for Dyskinesia and Hyperkinesia - Drug Profile
Small Molecules for Neurodegenerative Disease - Drug Profile
Small Molecules for Tardive Dyskinesia - Drug Profile
Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile
Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile
Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile
Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile
SOM-3355 - Drug Profile
TC-8831 - Drug Profile
tetrabenazine - Drug Profile
valbenazine tosylate - Drug Profile
Dyskinesia - Dormant Projects
Dyskinesia - Discontinued Products
Dyskinesia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 166

LIST OF TABLES

Number of Products under Development for Dyskinesia, H2 2016
Number of Products under Development for Dyskinesia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Dyskinesia - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016
Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2016
Dyskinesia - Pipeline by Advicenne, H2 2016
Dyskinesia - Pipeline by Astraea Therapeutics, LLC, H2 2016
Dyskinesia - Pipeline by Bionomics Limited, H2 2016
Dyskinesia - Pipeline by Catalyst Biosciences, Inc., H2 2016
Dyskinesia - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016
Dyskinesia - Pipeline by Clevexel Pharma SAS, H2 2016
Dyskinesia - Pipeline by Contera Pharma ApS, H2 2016
Dyskinesia - Pipeline by EpiVax, Inc., H2 2016
Dyskinesia - Pipeline by Heptares Therapeutics Limited, H2 2016
Dyskinesia - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016
Dyskinesia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016
Dyskinesia - Pipeline by Ipsen S.A., H2 2016
Dyskinesia - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016
Dyskinesia - Pipeline by MitoDys Therapeutics Limited, H2 2016
Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016
Dyskinesia - Pipeline by Neurocrine Biosciences, Inc., H2 2016
Dyskinesia - Pipeline by Neurolixis Inc., H2 2016
Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp., H2 2016
Dyskinesia - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Dyskinesia - Pipeline by Phenomenome Discoveries, Inc., H2 2016
Dyskinesia - Pipeline by Revance Therapeutics, Inc., H2 2016
Dyskinesia - Pipeline by Sage Therapeutics, Inc., H2 2016
Dyskinesia - Pipeline by SciFluor Life Sciences, LLC, H2 2016
Dyskinesia - Pipeline by SOM Innovation Biotech SL, H2 2016
Dyskinesia - Pipeline by Synchroneuron Inc., H2 2016
Dyskinesia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Dyskinesia - Dormant Projects, H2 2016
Dyskinesia - Dormant Projects (Contd..1), H2 2016
Dyskinesia - Dormant Projects (Contd..2), H2 2016
Dyskinesia - Discontinued Products, H2 2016 153

LIST OF FIGURES

Number of Products under Development for Dyskinesia, H2 2016
Number of Products under Development for Dyskinesia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Tardive Dyskinesia - Pipeline Review, H2 2015 US$ 1,600.00 Jul, 2015 · 56 pages

Ask Your Question

Dyskinesia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: